<DOC>
	<DOCNO>NCT02299414</DOCNO>
	<brief_summary>The purpose study evaluate whether blood pressure treatment strategy pregnancy achieve target recommend non-pregnant reproductive-age adult ( &lt; 140/90 mmHg ) compare ACOG- recommended standard pregnancy ( treatment unless BP severe ) effective safe .</brief_summary>
	<brief_title>Chronic Hypertension Pregnancy ( CHAP ) Project</brief_title>
	<detailed_description>During pregnancy , chronic hypertension ( CHTN ) common major medical disorder encounter , occur 2-6 % . The substantial negative effect CHTN pregnancy include consistent 3- 5-fold increase superimpose preeclampsia adverse perinatal outcome ( fetal neonatal death , preterm birth -PTB , poor fetal growth placental abruption ) possibly 5- to10-fold increase maternal cardiovascular complication ( death , cerebrovascular accident , pulmonary edema acute renal failure ) . Mild CHTN ( BP &lt; 160/110 ) contributes large proportion adverse outcome . While antihypertensive treatment CHTN standard general population , uncertain whether treatment pregnancy reduce maternal fetal complication , concern decrease arterial pressure may reduce fetal blood flow cause poor fetal growth small-for-gestational-age ( SGA ) infant . Some authority , include American College Obstetricians Gynecologists ( ACOG ) American Society Hypertension ( ASH ) recommend withhold antihypertensive therapy mild CHTN , particularly BP &lt; 160/105-110 mmHg . The recommendation withhold antihypertensive treatment pregnancy conflict broader public health goal reduce BP CHTN evidence discontinue therapy brief period pregnancy affect maternal outcome ( reduce severe hypertension ) . For decade , authority consistently call well-designed powered trial delineate benefit risk pharmacologic therapy CHTN pregnancy . Therefore , multicenter consortium propose Chronic Hypertension Pregnancy ( CHAP ) Project , large pragmatic randomize trial primary aim evaluate benefit harm pharmacologic treatment mild CHTN pregnancy .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Labetalol</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>1 . Women chronic hypertension pregnancy new untreated chronic hypertension , blood pressure 140159 systolic 90104 diastolic OR know chronic hypertension monotherapy take antihypertensive blood pressure ≤159/104 ( include blood pressure &lt; 140/90 ) ; 2 . Singleton ; 3. viable pregnancy &lt; 23 week gestation . 1 . Blood pressure prior randomization ≥160 systolic ≥105 diastolic ( without treatment ) ; 2 . Patients currently treat &gt; 1 antihypertensive medication ( likely severe chronic hypertension ) ; 3 . Multifetal pregnancy ; 4 . Known secondary cause chronic hypertension ; 5 . Highrisk comorbidities treatment may indicate : Class C high diabetes mellitus Chronic kidney disease include baseline proteinuria ( &gt; 300mg/24hr , p/c ratio &gt; 0.3 , persistent 1+ proteinuria* ) creatinine &gt; 1.2 . *If dipstick value screen trace , clean catch catheter urine obtain retested dipstick . If show trace absence protein , patient include . If show 1+ protein , patient exclude 24hr urine &lt; 300mg/24hr p/c ratio &lt; 0.3 . Cardiac disorder : cardiomyopathy , angina , CAD Prior stroke Retinopathy Sickle cell disease ; 6 . Known major fetal anomaly ; 7 . Known fetal demise ; 8 . Suspected IUGR ; 9 . Membrane rupture plan termination prior randomization ; 10 . Plan deliver outside consortium center ( unless approve Clinical Coordinating Center ) unlikely followup opinion study staff previous participation trial ; 11 . Contraindication labetalol nifedipine ( e.g . know hypersensitivity ) ; ( 12 ) Current substance abuse addiction ( cocaine , methamphetamine ) *The minimum age varies center</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Chronic hypertension</keyword>
</DOC>